Skip to content

A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis

A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06132048
Acronym
MuControl-Sum
Enrollment
17
Registered
2023-11-15
Start date
2024-07-01
Completion date
2025-02-28
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The study aims to assess the usability and safety of use of MuCopilot, a smartphone application that measures objective data on lung function, global exercise capacity and patient reported outcomes of patients with Cystic Fibrosis (CF). These data are collected during unsupervised digital tests performed in the patient's home environment between consultations. The primary objective is to validate the usability and safety of use, in order to assure that the patients use the medical device as intended without any unacceptable error of use and without unacceptable risk. The study will include 17 CF patients and will be conducted in France. They will participate in 1 inclusion visit and 1 visit in-clinic (1h30). Patients will be able to download the free MuCopilot mobile application. During the visit, patients will complete 3 digital tests in order to monitor CF functions (cough, dyspnea & walking) and 1 symptom questionnaire.

Interventions

MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life

Sponsors

Ad scientiam
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ⩾ 18 years old * Patients diagnosed with cystic fibrosis * Enrolled in or benefiting of a Social Security program * Having read the information sheet and signed the informed consent form * Owning a personal smartphone which version is above 14 for IOS and 8 for Android included with a good internet connexion * Able to read French and understand pictograms on a smartphone app

Exclusion criteria

* History of lung transplantation * Pregnant women and women who are breastfeeding * Any medical condition that could interfere with the proper conduct and results of the study (clinician's judgement) * Illiterate in French * Inability to use a smartphone or MuCopilot application * Person under legal protection (including guardianship or curatorship)

Design outcomes

Primary

MeasureTime frameDescription
Validation of usability (1)2 hoursUse error : Any deviation from the instructions for use that does not result in a response from the medical device other than what the manufacturer intended. Validated if there is no unacceptable use error.
Validation of usability (2)2 hoursTask completion rate: percentage of use scenarios completed without observation of an unacceptable error. The unacceptable nature of an error is determined according to the risk analysis process covered by ISO 14971:2019. Validated if the success rate on each task must reach 78% at minimum.
Validation of no safety critical of use2 hoursSafety critical error: a user error that causes a safety incident, where safety is defined as the appearance of a hazardous situation and the related harms linked to an unacceptable risk, as stated in the application version of Risk Analysis. Validated if there is no safety critical error has been identified during the evaluation.
Validation of ease of use2 hoursThe MuCopilot solution will be considered as easy to use, if the perceived ease of use mean score reaches 7.8/10

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026